TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06016920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg intravenous (i.v.) will be given in accordance with the local regulatory-approved label Q3W starting at Week 1/Day 1 for as long as the patient tolerates and continues to have clinical benefit from the treatment based on the patient and investigator's decision, up to a maximum of 35 treatments corresponding to approximately 2 years of treatment.~After 48 weeks of treatment patients can continue on 200 mg Q3W or change to 400 mg Q6W at the discretion of the investigator and after consultation with the sponsor.~Pembrolizumab will be given by i.v. infusion over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg intravenous (i.v.) will be given in accordance with the local regulatory-approved label Q3W starting at Week 1/Day 1 for as long as the patient tolerates and continues to have clinical benefit from the treatment based on the patient and investigator's decision, up to a maximum of 35 treatments corresponding to approximately 2 years of treatment.~After 48 weeks of treatment patients can continue on 200 mg Q3W or change to 400 mg Q6W at the discretion of the investigator and after consultation with the sponsor.~Pembrolizumab will be given by i.v. infusion over 30 minutes.
Study: NCT05235217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test product (T) 40 mg Hard Gelatin Capsules
Description: Hard Gelatin Capsules products containing 40 mg Esomeprazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference product (R) 40 mg Hard Gelatin Capsules
Description: Reference product (R) 40 mg Hard Gelatin Capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference product (R) 40 mg Hard Gelatin Capsules
Description: Reference product (R) 40 mg Hard Gelatin Capsules
Study: NCT06186752

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyIBD
Description: MyIBD has two components: (1) an electronic, templated document that presents brief, actionable, tailored guidance from IBD specialists to families and other providers who care for a pediatric patient with IBD; and (2) regular, short prompts sent through the electronic patient portal to remind patients to refer to and use their MyIBD document to guide decisions about care in between appointments.
Study: NCT06082752

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Massage session
Description: Participants in the intervention group are provided with the 5-minute massage session in the medial and lateral gastrocnemius muscle (dominant leg).
Study: NCT05855317

Intervention type: OTHER
Intervention: Blood sample
Description: Additional blood samples will be taken on a catheter, used for standard care.

Intervention type: OTHER
Intervention: Blood sample
Description: Additional blood samples will be taken on a catheter, used for standard care.
Study: NCT05178056

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Cord Epidural Stimulation
Description: Spinal Cord Epidural Stimulation (scES) will be administered by a multi-electrode array (5-6-5 SpecifyTM electrode, MEDTRONIC, Minneapolis, MN, USA) previously implanted in the epidural space over the dorsum of the spinal cord.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Epidural Stimulation
Description: Spinal Cord Epidural Stimulation (scES) will be administered by a multi-electrode array (5-6-5 SpecifyTM electrode, MEDTRONIC, Minneapolis, MN, USA) previously implanted in the epidural space over the dorsum of the spinal cord.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory Training
Description: Standard threshold Positive Expiratory Pressure Device and standard threshold Inspiratory Muscle Trainer (Respironics Inc., Cedar Grove, NJ) assembled together will be used for respiratory training sessions to complete eighty 45-minute sessions during 16 weeks. The participants will be instructed to perform inspiratory and expiratory efforts against a pressure treshold load.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory Training
Description: Standard threshold Positive Expiratory Pressure Device and standard threshold Inspiratory Muscle Trainer (Respironics Inc., Cedar Grove, NJ) assembled together will be used for respiratory training sessions to complete eighty 45-minute sessions during 16 weeks. The participants will be instructed to perform inspiratory and expiratory efforts against a pressure treshold load.
Study: NCT05779579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10517 Dose 1
Description: HS-10517 Dose 1+Ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10517 Dose 2
Description: HS-10517 Dose 2+Ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10517 Dose 3
Description: HS-10517 Dose 3+Ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10517 Dose 4
Description: HS-10517 Dose 4+Ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dose level A of placebo
Study: NCT05145478

Intervention type: DEVICE
Intervention: Shockwave Intravascular Lithotripsy (IVL)
Description: Eligible patients with atherosclerotic lesions in the femoral artery who either have claudication or critical limb ischemia will receive endovascular treatment in addition to be treated with Shockwave Intravascular Lithotripsy (IVL) technology.
Study: NCT05715957

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05488080

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Department-level audit and feedback and electronic health record-embedded clinical decision support
Description: This intervention will provide clinicians with Equity Report Cards and clinician decision support on mitigating disparities in quality of care.
Study: NCT05601024

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laughter Therapy
Description: The first component of intervention is the laughter therapy that is a combination of warm up exercise, deep breathing exercises, childlike playfulness and laughter exercises. Participants will do laughter therapy with whatsapp group call. Each group will consist of at least 5 people. Each session of laughter therapy will be offered one a weekly and 30-40 minutes each time.
Study: NCT05583539

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Thromboelastography
Description: Thromboelastography is a viscoelastic test that measures the dynamics of blood clotting on whole blood samples.
Study: NCT06182397

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MagicTouch PTA Sirolimus drug coated balloon
Description: All patients must first be treated with pre dilatation with a standard balloon angioplasty using any standard balloon catheters at the discretion of the operator. Magic Touch PTA Sirolimus coated balloon catheter is an adjunct treatment that should be used in combination with standard balloon angioplasty. Following successful crossing of wire across the lesion and plain balloon angioplasty of arterial lesion with successful lesion preparation with residual lesion \<30%, subjects will be randomized to receive study device balloon. If patients are assigned to MagicTouch PTA Sirolimus DCB, the Angioplasty of lower limb will be performed with this device in addition to standard balloon angioplasty.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo balloon angioplasty
Description: For participants randomized to a Placebo balloon angioplasty group, a Placebo balloon angioplasty in addition to standard balloon angioplasty will be performed.
Study: NCT06338241

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Biphasic bioceramic of tricalcium phosphate and hydroxyapatite with simvastatin
Description: The intervention description for Galibone+ in the study involves the application of this substance to promote bone regeneration following the extraction of impacted mandibular third molars. Galibone is indicated to treat segmental and cavity bone loss, aesthetic repairs and bone augmentations (such as inlay or onlay grafts); to fill dental alveolar bone; for the placement of dental implants; for the stabilization of osteotomies and prostheses in dentistry.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bovine Hydroxyapatite
Description: The intervention description for Bio-Oss in the study involves the application of this standard material to promote bone regeneration following the extraction of impacted mandibular third molars. Bio-Oss is a commonly used xenograft material known for its osteoconductive properties.
Study: NCT05866393

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clean Hands Accessible and Manageable for Patients
Description: Use of a patient-smart hand sanitation dispenser that provides reminders that are non-beeping reminders.
Study: NCT06175962

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRAINING AND EXERCISE
Description: Menopause health training will take place in 2 sessions each week and will be completed in 4 sessions. Each session duration is 45 minutes. Baduanjin exercise training will take place in 2 sessions per week, each session lasting 30 minutes. It will be completed in 8 sessions in total. Relaxing music will be played during the Baduanjin exercise and relaxation will be encouraged. During the Baduanjin exercise, proper posture, conscious breathing and focus of the mind will be prioritized. While the movements are being implemented, their symbolic meanings will be explained to the participants. Women will be asked to perform baduanji 3 times a week for 8 weeks.~During this process, reminder messages will be sent to women via WhatsApp.
Study: NCT06155071

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric Training
Description: The group will receive plyometric exercises in a controlled environment. Following Plyometrics would be performed.~1. Plyo Pushup.~2. Chest Pass.~3. Overhead Throw.~4. Squat jump.~5. Plyo Step-up.~6. Cone jumps.~7. Med Ball drop.~8. Kneeling Squat jump.~9. Lateral jump over hurdle.~10. Overhead throw.~11. Under hand throws.~12. Dynamic Rotational Chest pass.~13. Overhead throw with step.
Study: NCT05552534

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STIR PROTOCOL
Description: Screening, STIR protocol (screening, brief intervention, incentive to download the tobacco info service application, delivery of the tobacco-info-service brochure, initiation of a nicotine patch made by the trained emergency nurse or doctor) then three consultations face-to-face or remotely with a member of the team addictionology at 7 days, 1 and 3 months.
Study: NCT05566652

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neural Pressure Support
Description: To evaluate WOB and asynchronies in patients with low respiratory system compliance undergoing either PSV and NPS.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Neural Pressure Support
Description: To evaluate WOB and asynchronies in patients with low respiratory system compliance undergoing either PSV and NPS.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation
Description: To evaluate WOB and asynchronies in patients with low respiratory system compliance undergoing either PSV and NPS.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Pressure Support Ventilation
Description: To evaluate WOB and asynchronies in patients with low respiratory system compliance undergoing either PSV and NPS.
Study: NCT06388837

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Injectable Platelet Rich Fibrin
Description: Patients underwent mandibular symphysis Onlay bone graft mixed with injectable platelet rich fibrin (I-PRF) placement.
Study: NCT06351618

Intervention type: OTHER
Intervention: No intervention will be conducted.
Description: No intervention will be conducted.
Study: NCT06388837

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Xenograft
Description: Patients underwent mandibular symphysis Onlay bone graft mixed with Xenograft (InterOss® Anorganic Cancellous Granules).
Study: NCT05400005

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary protein
Description: Intervention of the study include consuming a higher protein diet. Depending on the group allocation, this is done by asking the subjects to follow My Healthy Plate diet and consumption of 20g of protein isolates (casein or soy).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary protein
Description: Intervention of the study include consuming a higher protein diet. Depending on the group allocation, this is done by asking the subjects to follow My Healthy Plate diet and consumption of 20g of protein isolates (casein or soy).
Study: NCT06155071

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Exercises
Description: The group will receive conventional exercises in a controlled environment. Following conventional exercises would be performed.~1. Pushups.~2. Situps.~3. Lunges 4.500m running.~5.Squats
Study: NCT05500040

Intervention type: BEHAVIORAL
Intervention: Multimodal Rehabilitation
Description: The rehabilitation measure is based on the biopsychosocial ICF model of the WHO. A multidisciplinary team of therapists looks after the patients during their stay in rehabilitation. Taking into account the physical and psychological condition of the patients, an individual therapy plan is created that is tailored to their needs.

Intervention type: BEHAVIORAL
Intervention: Multimodal Rehabilitation
Description: The rehabilitation measure is based on the biopsychosocial ICF model of the WHO. A multidisciplinary team of therapists looks after the patients during their stay in rehabilitation. Taking into account the physical and psychological condition of the patients, an individual therapy plan is created that is tailored to their needs.
Study: NCT06372067

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intramedullary screw
Description: Intramedullary (IM) screw fixation is a minimally invasive technique that provides rigid fixation of fractures, acting as an internal splint and load-sharing device. IM screw fixation may allow for early mobilization without the operative site morbidity of open reduction and its associated complications.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kirschner wire
Description: Kirschner wire (K-wire) fixation is a minimally invasive technique that provides non-rigid fixation of fractures. K-wires allow for fracture fixation with minimal soft tissue injury and preserved blood supply. However, patients require prolonged postoperative immobilization and are at risk of malunion and pin tract infection.
Study: NCT05763160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RZL-012
Description: Ready to use drug product for injection into the subcutaneous fat
Study: NCT06553950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox injection
Description: Patients will be treated by Botox injection in lateral pterygoid muscle and medications like muscle relaxants, antidepressants and nonsteroidal anti-inflammatory drugs.~A Botox-A vial was diluted with normal saline to a concentration of 10 U per 0.1 mL for injection in a 1-ml insulin syringe. This will be injected into the ipsilateral lateral pterygoid muscle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mandibular stabilization splint
Description: Patients will be treated by mandibular stabilization splint and medications like muscle relaxants, antidepressants and nonsteroidal anti-inflammatory drugs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Muscle relaxant
Description: Patients will be treated by medications like muscle relaxants, antidepressants and nonsteroidal anti-inflammatory drugs.
Study: NCT05542888

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sacroiliac joint mobilization
Description: Sacroiliac joint mobilization will be performed with the patient in side lying position in which grade I,II pain relief mobilization will be given in PA direction.It will be given as 1 set of 30 oscillations per session, 3 times per week for 4 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Postural education, Hot pack, Antenatal exercises

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard therapy
Description: Postural education, Hot pack, Antenatal exercises
Study: NCT06310096

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TLF fascial stretching exercise
Description: Relaxed lumbo-pelvic upright sitting with arms in neutral anatomical position (O'Sullivan et al., 2006). The subjects had to bend both knee flexed 90. The feet of the Participant lied flat on the ground. Trunk was in aligned position and the angle between upper body and lower body was 90. Seated position led to caudal tensioning of the pTLF via stretching of the gluteus maximus (GM)~Seated position with passive arms elevation Seated position with passive caudal stretching of TLF through thigh elevation. The subjects had to bend both hips while keeping their feet onto a stool (30 cm high) so to pull the GM and the TLF

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physiotherapy program.
Description: hotpack, ultrasound ,Tens
Study: NCT05747495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online training in CPR-AED
Description: The online training has been designed according to the Catalan Resuscitation Council (CCR) and the European Resuscitation Council (ERC) guidelines. The aim of this training is to provide theoretical and practical knowledge to respond to aid situations (from unconscious people to drowning, both adults and children), as well as the use of the AED.~The contents are available at the link \[https://register.magnore.com/registre-curs-de-reanimacio-cardiopulmonar-dea/\].
Study: NCT05686434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: This is a prospective, open, single-center, single-arm phase II clinical study with EGFR-sensitive mutations (Ex19del and L858R) identified in the central laboratory，to evaluate the efficacy and safety of adjuvant Osimertinib therapy in completely resected stage I non-squamous non-small cell lung cancer (NSCLC) with high-risk factors (solid and/or micropapillary component ≥10%, and/or airway spread).
Study: NCT04903119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib 100mg
Description: Patients will begin dabrafenib (150mg PO BID) and trametinib (2mg PO once daily) on day one and will continue for 28 days. After 7 days, nilotinib will be added at 100mg PO BID and will continue for 21 days. For each subsequent cycle, nilotinib will be given for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib 200mg
Description: Patients will begin dabrafenib (150mg PO BID) and trametinib (2mg PO once daily) on day one and will continue for 28 days. After 7 days, nilotinib will be added at 200mg PO BID and will continue for 21 days. For each subsequent cycle, nilotinib will be given for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib 300mg
Description: Patients will begin dabrafenib (150mg PO BID) and trametinib (2mg PO once daily) on day one and will continue for 28 days. After 7 days, nilotinib will be added at 300mg PO BID and will continue for 21 days. For each subsequent cycle, nilotinib will be given for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib 400mg
Description: Patients will begin dabrafenib (150mg PO BID) and trametinib (2mg PO once daily) on day one and will continue for 28 days. After 7 days, nilotinib will be added at 400mg PO BID and will continue for 21 days. For each subsequent cycle, nilotinib will be given for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: All patients will begin dabrafenib (150mg PO BID) on day one and will continue for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: All patients will begin dabrafenib (150mg PO BID) on day one and will continue for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: All patients will begin dabrafenib (150mg PO BID) on day one and will continue for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: All patients will begin dabrafenib (150mg PO BID) on day one and will continue for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: All patients will begin trametinib (2mg PO once daily) on day one and will continue for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: All patients will begin trametinib (2mg PO once daily) on day one and will continue for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: All patients will begin trametinib (2mg PO once daily) on day one and will continue for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: All patients will begin trametinib (2mg PO once daily) on day one and will continue for 28 days.
Study: NCT05007249

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Use of the Chalaxie pedagogical evaluation tool
Description: Use of the Chalaxie pedagogical evaluation tool during two visits
Study: NCT05446025

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: Orexigenic hormones (appetizing) Orexin, galanin and anorexigenic hormones (decreasing appetite) aMSH and CART blood levels will be measured

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: Orexigenic hormones (appetizing) Orexin, galanin and anorexigenic hormones (decreasing appetite) aMSH and CART blood levels will be measured
Study: NCT04853524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56136379
Description: JNJ-56136379 tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF)
Description: A combination of BIC, FTC and TAF will be administered orally.
Study: NCT05270850

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Conventional treatment for benign airway stenosis Including, but is not limited to laser, high-frequency electric knife, argon plasma coagulation (APC), cryotherapy, balloon dilation, and metal stent placement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SVF group
Description: SVF treatment following the conventional treatment for benign airway stenosis and respiratory tract fistula